BlossomHill eyes $112M IPO harvest to fund Tagrisso challenger
BlossomHill Therapeutics eyes a $112M IPO to bankroll development of a potential challenger to AstraZeneca's blockbuster EGFR inhibitor Tagrisso.
BlossomHill Therapeutics
Private
Clinical-stage biotech developing oncology therapies for non-small cell lung cancer, with a lead Tagrisso-chasing EGFR-targeted program.
Company Info
Sector:Biotechnology
Headquarters:South San Francisco, California, USA
Founded:2018
Website:bhtherapeutics.com/
Upcoming Milestones & Key Dates
2026 IPO
Capital Markets
Expected Nasdaq IPO listing
Late 2026
Clinical Readout
Initial Phase 1/2 dose-escalation data
Clinical Development Pipeline
BH-3060
Target: EGFRUndisclosed
Target: TBDUndisclosed
Target: TBDRecent News
BlossomHill eyes IPO to grow taller in crowded cancer fields
BlossomHill eyes IPO to grow taller in crowded cancer fields.
Tagrisso-chasing BlossomHill enters Nasdaq queue as biotech IPOs flourish
BlossomHill Therapeutics enters the Nasdaq queue with a Tagrisso-chasing oncology program.
Leadership Team
Management Team
Founders and Executive Leadership
Clinical Leadership
Chief Medical Officer
Scientific Leadership
Chief Scientific Officer
Careers & Job Openings